[1]马一鸣,陈红敏,邓君丽,等.局部晚期宫颈癌组织中ERCC1 mRNA表达及DNA倍体与新辅助化疗效果的关系*[J].郑州大学学报(医学版),2014,(02):233.
 MA Yiming,CHEN Hongmin,DENG Junli,et al.Relationship of expression of ERCC1 mRNA and DNA ploidy in locally advanced cervical cancer tissue to curative effect of neoadjuvant chemotherapy[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(02):233.
点击复制

局部晚期宫颈癌组织中ERCC1 mRNA表达及DNA倍体与新辅助化疗效果的关系*
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2014年02期
页码:
233
栏目:
应用研究
出版日期:
2014-03-20

文章信息/Info

Title:
Relationship of expression of ERCC1 mRNA and DNA ploidy in locally advanced cervical cancer tissue to curative effect of neoadjuvant chemotherapy
作者:
马一鸣陈红敏邓君丽阎夏窦萌萌王莉#
郑州大学附属肿瘤医院妇瘤科;河南省肿瘤医院妇瘤科 郑州 450003
Author(s):
MA YimingCHEN HongminDENG JunliYAN XiaDOU MengmengWANG Li
Department of Gynecologic Oncology,the Affiliated Cancer Hospital, Zhengzhou University; Henan Provincial Cancer Hospital,Zhengzhou 450003
关键词:
局部晚期宫颈癌ERCC1DNA倍体新辅助化疗
Keywords:
locally advanced cervical cancerERCC1DNA ploidyneoadjuvant chemotherapy
分类号:
A
文献标志码:
R737.33
摘要:
目的:探讨局部晚期宫颈癌(LACC)组织中ERCC1 mRNA表达和DNA倍体与新辅助化疗(NACT)敏感性的关系。方法:收集60例LACC患者NACT前宫颈活检标本,应用PCR结合实时荧光探针技术分析标本中ERCC1 mRNA的表达情况,采用细胞DNA定量分析技术分析DNA倍体。结果:60例患者中NACT有效33例,有效率为55.0%。LACC组织中ERCC1 mRNA表达水平、DNA倍体与NACT疗效有关(P<0.05);logistic回归模型分析结果也显示,LACC组织中ERCC1 mRNA高表达是NACT疗效的负性影响因素[β=-2.672,OR(95%CI)=0.069(0.008~0.583)], DNA二倍体则是正性影响因素[β=1.348,OR(95%CI)=3.850(1.134~13.075)]。结论:LACC组织中ERCC1、DNA倍体表达与NACT敏感性密切相关。
Abstract:
Aim: To explore relationship between the effect of neoadjuvant chemotherapy(NACT) and the expression of ERCC1 mRNA,DNA ploidy in locally advanced cervical cancer(LACC) tissue. Methods: A total of 60 cases of LACC biopsy specimens before chemotherapy were collected. PCR combined with the fluorescence probe technique were applied to analyze the expression of ERCC1 mRNA in the specimens, and the DNA quantitative analysis technique was adopted to analyze DNA ploidy.Results: Thirtythree cases were effective in the 60 patients, and the effective rate was 55.0%.There was a correlation between ERCC1 mRNA expression, DNA ploidy and the curative effect of NACT(P<0.05). The result of logistic regression showed that high expression of ERCC1 mRNA was a negative factor for curative effect of NACT[β=-2.672,OR(95%CI)=0.069(0.008-0.583)],and DNA diploid was a positive factor[β=1.348,OR(95%CI)=3.850(1.134-13.075)]. Conclusion: The expression of ERCC1 mRNA and DNA ploidy in LACC tissue may be related to the sensitivity of NACT.

参考文献/References:

[1]Liu Y,Scheurer ME,EIZein R,et al.Association and interactions between DNA repair gene polymorphisms and adult glioma[J].Cancer Epidemiol Biomarkers Prev,2009,18(1):204 [2]徐锦慧.DNA倍体分析及巴氏涂片细胞检测在宫颈癌筛查中的对比研究[J].临床合理用药杂志,2012,5(6):15 [3]王旭波,刘凌,贾晓民,等.DNA倍体、PCNA表达与放射敏感细胞对宫颈癌诊断和放疗效果判定的研究[J].南京医科大学学报:自然科学版,2008,28(2):236 [4]中华医学会妇产科分会,中华妇产科杂志编辑委员会.妇科常见肿瘤诊断与治疗规范(草案)[J].中华妇产科杂志,1998,33(11):694 [5]Mabuchi S,Ugaki H,Isohashi F,et al.Concurrent weekly nedaplatin, external beam radiotherapy and highdoserate brachytherapy in patients with FIGO stage Ⅲb cervical cancer:a comparison with a cohort treated by radiotherapy alone[J].Gynecol Obstet Invest,2010,69(4):224 [6]彭方慧,王峰,何炜,等.替吉奥与5氟尿嘧啶联合奈达铂治疗晚期食管癌的疗效比较[J].郑州大学学报:医学版,2013,48(2):160 [7]王先国,朱红,朱琳.奈达铂联合诺维本治疗晚期食管癌的临床疗效观察[J].现代肿瘤医学,2010,18(4):716 [8]Kawase S,Okuda T,Ikeda M,et al.Intraarterial cisplatin/nedaplatin and intravenous 5fluorouracil with concurrent radiation therapy for patients with highrisk uterine cervical cancer[J].Gynecol Oncol,2006,102(3):493 [9]Altaha R,Liang X,Yu JJ,et al.Excision repair cross complementinggroup1:gene expression and platinum resistance[J].Int J Mol Med,2004,14(6):959 [10]Ferry KV,Hamilton TC,Johnson SW.Increased nudeotide excision repair in cisplatinresistant ovarian cancer cells: role of ERCC1XPF[J].Biochem Pharmacol,2000,60(9):1305 [11]韩越,梁军,吕红英,等.晚期非小细胞肺癌ERCC1 XRCC1基因多态性与铂类化疗疗效研究[J].中国实用内科杂志,2011,31(8):638 [12]陈昱丞,张明智,张旭东,等.抗微管类、铂类药物对人淋巴细胞系体外敏感性实验及TVBB3、ERCC1表达的相关性分析[J].西安交通大学学报:医学版,2012,33(5):539 [13]杨艳,于廷和.ERCC1与顺铂耐药的研究进展[J].肿瘤,2007,27(12):1008

备注/Memo

备注/Memo:
*河南省科技攻关计划项目102102310107 #通讯作者,女,1964年8月生,本科,主任医师,研究方向:妇科肿瘤的诊治,Email:13837196622@163.com
更新日期/Last Update: 2014-04-23